Breaking News Instant updates and real-time market news.

FL

Foot Locker

$46.71

2.38 (5.37%)

, UA

Under Armour; also tag UAA

$13.52

1.0749 (8.63%)

10:22
12/15/17
12/15
10:22
12/15/17
10:22

On The Fly: Top five analyst upgrades

Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Foot Locker (FL) upgraded to Buy from Hold by Canaccord analyst Camilo Lyon, who believes the company is approaching the end of the inventory clearance cycle it has been in for the past three quarters and that the company's relationship with Nike (NKE) is "strong and symbiotic." 2. Stifel analyst Jim Duffy upgraded Under Armour (UAA) to Buy from Hold, saying he expects the company's business to be in a much better position entering 2019 and for the stock to begin to anticipate improvements before it shows in reported results. 3. Argus analyst John Staszak upgraded Skechers (SKX) to Buy from Hold with a price target of $44, citing signs that a recovery in the company's domestic wholesale business has commenced. 4. Goldman analyst Robert Jones upgraded AmerisourceBergen (ABC) to Buy from Neutral, telling investors he believes an EBIT inflection in FY18 is coming. 5. Goldman Sachs analyst Jami Rubin added BioMarin (BMRN) and Alnylam (ALNY) to the firm's Conviction Buy List, upgrading them both from Buy. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.

FL

Foot Locker

$46.71

2.38 (5.37%)

UA

Under Armour; also tag UAA

$13.52

1.0749 (8.63%)

UAA

Under Armour; also tag UA

$14.97

1.15 (8.32%)

CRTO

Criteo

$24.42

-7.19 (-22.75%)

SKX

Skechers

$38.07

1.15 (3.11%)

BMRN

BioMarin

$88.53

-0.13 (-0.15%)

ALNY

Alnylam

$123.66

-1.2 (-0.96%)

  • 08

    Jan

  • 28

    Feb

FL Foot Locker
$46.71

2.38 (5.37%)

12/04/17
12/04/17
DOWNGRADE

Hold
Foot Locker downgraded to Hold with 'rare loss' at Standpoint Research
As previously reported, Standpoint Research analyst Ronnie Moas downgraded Foot Locker to Hold from Buy, saying it "is very rare for me to close a position out at a loss" but following the 60% bounce from the stock's low he is doing that in this case. Moas now wonders if Foot Locker is a value trap given declining shopping mall numbers and foot traffic in the U.S.
12/04/17
STPT
12/04/17
DOWNGRADE
STPT
Hold
Foot Locker downgraded to Hold from Buy at Standpoint Research
12/15/17
12/15/17
UPGRADE
Target $64

Buy
Foot Locker upgraded to Buy on end of inventory clearance at Canaccord
As previously reported, Canaccord analyst Camilo Lyon upgraded Foot Locker (FL) to Buy from Hold, stating that he believes the company is approaching the end of the inventory clearance cycle it has been in for the past three quarters. His recent travels with management made it clear that the company's relationship with Nike (NKE) is "strong and symbiotic" and that recent comp declines are due to cyclical factors, not structural ones, he added. Lyon raised his price target on Foot Locker shares to $64 from $42.
12/15/17
ADAM
12/15/17
UPGRADE
ADAM
Buy
Foot Locker upgraded to Buy from Hold at Canaccord
UA Under Armour; also tag UAA
$13.52

1.0749 (8.63%)

11/15/17
BARD
11/15/17
NO CHANGE
Target $17
BARD
Outperform
Under Armour showing signs of better demand and execution, says Baird
Baird analyst Jonathan Komp said there are signs for Under Armour of better reception for the Curry 4 basketball shoe and better execution too. He believes it may still be early but the rebound in the Curry shoe, continued international strength, and broadening distribution could provide ingredients for a return to healthier footwear growth in the upcoming quarters. Komp maintained his Outperform rating and $17 price target on Under Armour shares.
12/15/17
STFL
12/15/17
UPGRADE
Target $17
STFL
Buy
Under Armour upgraded to Buy from Hold at Stifel
Stifel analyst Jim Duffy upgraded Under Armour to Buy from Hold, saying he expects the company's business to be in a much better position entering 2019 and for the stock to begin to anticipate improvements before it shows in reported results. Duffy, who is looking for a return to full-price apparel and footwear sales at retail and signs of margin improvement, raised his price target on Under Armour shares to $17 from $12.
11/22/17
STFL
11/22/17
NO CHANGE
Target $12
STFL
Hold
Under Armour continued executive turnover 'troubling,' says Stifel
After The Wall Street Journal reported that Peter Ruppe, SVP of Footwear, will be leaving Under Armour, Stifel analyst Jim Duffy noted that this follows a number of other senior executive departures in the past twelve months, which he sees suggesting "troubling" instability and lack of clear direction. However, the recent addition of Patrik Frisk as President and COO holds promise to introduce leadership continuity, said Duffy, who keeps a Hold rating and $12 price target on Under Armour shares.
12/14/17
DBAB
12/14/17
UPGRADE
Target $11
DBAB
Hold
Finish Line upgraded to Hold from Sell at Deutsche Bank
Deutsche Bank analyst Paul Trussell upgraded Finish Line (FINL) to Hold and raised his price target for the shares to $11 from $5. The analyst sees sector headwinds alleviating in fiscal 2018 as Nike (NKE) delivers product newness and overall inventory levels scale back, leading to a less promotional environment. He believes Finish Line's efforts to improve assortment, store experience and vendor relationships will lead to a modestly better sales results. Trussell also raised his price target for Nike shares to $76 from $61 and for Under Armour (UAA) to $12 from $11.
UAA Under Armour; also tag UA
$14.97

1.15 (8.32%)

CRTO Criteo
$24.42

-7.19 (-22.75%)

12/15/17
MACQ
12/15/17
UPGRADE
MACQ
Outperform
Criteo upgraded to Outperform, risk/reward skewed to upside, says Macquarie
Macquarie analyst Tim Nollen upgraded Criteo to Outperform from Neutral but lowered its price target to $30 from $44 saying the company "kitchened-sinked" the impact of ITP and risk/reward is now skewed to the upside. The analyst said Apple's (AAPL) recent update to iOS11.2 has rendered Criteo's workaround to offset about half of the revenue impact due to lost user cookies from Safari tracker blocking as useless, removing 22% of revenue ex-tac. Nollen believes Criteo still offers highly targetable marketing on 78% of web browsing, which is still a valuable service and views the company's "worst case" as the new "base case." Note JMP Securities and Citibank both downgraded Criteo this morning.
12/15/17
JMPS
12/15/17
DOWNGRADE
JMPS
Market Perform
Criteo downgraded to Market Perform from Outperform at JMP Securities
JMP Securities analyst Andrew Boone downgraded Criteo (CRTO) to Market Perform from Outperform, citing uncertainty around the company's release of its Intelligent Tracking Prevention solution and Apple's (AAPL) potential response. He is also concerned about the unknown effects of General Data Protection Regulation, which is coming in 2018 and could increase data regulation in Europe, he tells investors.
12/15/17
SBSH
12/15/17
DOWNGRADE
Target $28
SBSH
Neutral
Criteo downgraded to Neutral from Buy at Citi
Citi analyst Mark Kelley downgraded Criteo (CRTO) to Neutral and lowered his price target for the shares to $28 from $51. Apple (AAPL) clearly wants to stop Criteo's workarounds, Kelley tells investors in a research note. He sees too much uncertainty around the business to recommend the shares.
12/15/17
RHCO
12/15/17
NO CHANGE
Target $35
RHCO
Buy
Criteo price target lowered to $35 from $51 at SunTrust
SunTrust analyst Matthew Thornton lowered his price target on Criteo (CRTO) to $35, noting that the Apple (AAPL) iOS update "knocked out" the company's ITP workaround to target Safari users. Thornton keeps his Buy rating, saying that the biggest uncertainty for Criteo has now been removed, and the company's new workaround, which is currently in development with more details expected in February, could serve as a new catalyst. The analyst also notes an increasing possibility of a stock buyback.
SKX Skechers
$38.07

1.15 (3.11%)

10/20/17
SUSQ
10/20/17
NO CHANGE
Target $38
SUSQ
Positive
Skechers price target raised to $38 from $34 at Susquehanna
Susquehanna analyst Sam Poser raised his price target on Skechers to $38 from $34 citing international growth and healthy domestic business. He said continued top-line strength, coupled with slowing investment growth, sets the company up for an earnings inflection in 2018. Poser reiterated his Positive rating on Skechers shares.
12/15/17
ARGS
12/15/17
UPGRADE
Target $44
ARGS
Buy
Skechers upgraded to Buy at Argus on recovery in domestic wholesale business
As noted earlier, Argus analyst John Staszak upgraded Skechers to Buy from Hold with a price target of $44. Staszak says a recovery in the company's domestic wholesale business has commenced, with revenue growth seen accelerating from the 1.4% rate in Q3 on better U.S. retail comps. The analyst also notes rapid growth in Skechers' international business as it grows its percentage of total sales toward 50% by the end of this year. Longer term, Staszak says the company can perform thanks to its innovative products, expansion through new store count, and international distribution deals.
12/15/17
ARGS
12/15/17
UPGRADE
ARGS
Buy
Skechers upgraded to Buy from Hold at Argus
12/11/17
COWN
12/11/17
NO CHANGE
Target $42
COWN
Outperform
Cowen ups Skechers target to $42, calls best idea for 2018
Cowen analyst John Kernan raised his price target for Skechers to $42 from $38 and calls the stock a best idea for 2018. International growth and an improving product cycle in 2018 could produce upside to consensus estimates, Kernan tells investors in a research note. He sees Skechers receiving a higher multiple and keeps an Outperform rating on the shares.
BMRN BioMarin
$88.53

-0.13 (-0.15%)

12/15/17
GSCO
12/15/17
UPGRADE
Target $131
GSCO
Conviction Buy
BioMarin upgraded to Conviction Buy from Buy at Goldman Sachs
Goldman Sachs analyst Jami Rubin added BioMarin to the Conviction Buy List saying shares are poised to recover. Rubin expects BioMarin shares to be driven by an increasing base business of six orphan drugs driving FY17 guidance of $1.25B-$1.3B and peak sales of $2.4B in 2026, the broad pipeline with three pivotal programs that can contribute $2.8B in peak sales in 2026 and early programs not reflected in projections, non-GAAP profitability by year-end 2017, and an attractive M&A profile. The analyst has a $131 price target on BioMarin shares.
12/14/17
WEDB
12/14/17
UPGRADE
WEDB
Outperform
BioMarin upgraded to Outperform from Neutral at Wedbush
12/14/17
12/14/17
UPGRADE
Target $110

Outperform
BioMarin upgraded to Outperform at Wedbush
As previously reported, Wedbush analyst Liana Moussatos upgraded BioMarin to Outperform from Neutral on recent events, namely Valoctocogene Roxaparvovec gene therapy for severe Hemophilia A being in the lead and emerging as a potential single dose cure with recent data at ASH and published in the NEJM, increasing sales projections for BMN 270 and value for BioMarin, sale of a second PRV, near-term non-GAAP breakeven, and her view that a company selling FVIII for Hemophilia A may be willing to pay a premium for a commercial license or for BioMarin as BMN 270 could be a serious threat to the multi-billion dollar worldwide FVIII franchise. She also raised her price target on the shares to $110 from $108.
12/14/17
12/14/17
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Nike (NKE) upgraded to Buy from Hold at Argus with analyst John Staszak saying the company's "strong brand and product pipeline have enabled it to raise prices and increase sales of both its apparel and footwear." 2. Tiffany (TIF) upgraded to Buy from Neutral at Citi with analyst Paul Lejuez saying the shares look attractive as currency tailwinds and tax reform should benefit the company's earnings. 3. lululemon (LULU) upgraded to Buy from Hold at Deutsche Bank with analyst Paul Trussell saying the shares are only up 8% in the last 12 months and flat over the last five years. 4. Southwest (LUV) upgraded to Overweight from Neutral at Atlantic Equities with analyst Lindsay Bettiol saying he believes the company has a number of structural benefits when compared with legacy peers and he sees material upside to its free cash flow in coming years. 5. BioMarin (BMRN) upgraded to Outperform from Neutral at Wedbush with analyst Liana Moussatos citing recent events, namely Valoctocogene Roxaparvovec gene therapy for severe Hemophilia A being in the lead and emerging as a potential single dose cure with recent data at ASH and published in the NEJM, increasing sales projections for BMN 270 and value for BioMarin, sale of a second PRV, near-term non-GAAP breakeven, and her view that a company selling FVIII for Hemophilia A may be willing to pay a premium for a commercial license or for BioMarin as BMN 270 could be a serious threat to the multi-billion dollar worldwide FVIII franchise. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
ALNY Alnylam
$123.66

-1.2 (-0.96%)

12/15/17
GSCO
12/15/17
UPGRADE
GSCO
Conviction Buy
Alnylam upgraded to Conviction Buy from Buy at Goldman Sachs
Goldman Sachs analyst Jami Rubin added Alnylam to the Conviction Buy List telling investors the company is transitioning to a commercial-stage biotech company from a "platform" company and expects FDA approval of lead drug Patisiran in 2H18 and interim Phase 3 data results for second-late stage asset Givosiran in mid-2018. Rubin believes Alnylam's valuation only reflects 60% of total forecasted peak revenues, leaving significant upside. The analyst has a $115 price target on Alnylam shares.
11/17/17
PIPR
11/17/17
NO CHANGE
Target $182
PIPR
Overweight
Piper trims Alnylam target to $182 after capital raise
Piper Jaffray analyst Edward Tenthoff trimmed his price target for Alnylam Pharmaceuticals to $182 from $188 to account for dilution from the company's issuance of 6.44M shares at $125. The company's cash position of $1.93B will allow for the patisiran launch and pipeline advancements, Tenthoff tells investors in a research note. He reiterates an Overweight rating on Alnylam.
11/09/17
JPMS
11/09/17
UPGRADE
Target $162
JPMS
Overweight
Alnylam upgraded to Overweight from Neutral at JPMorgan
JPMorgan analyst Anupam Rama upgraded Alnylam Pharmaceuticals saying he believes patisiran "has definitively solidified" a dominant market position in the ATTR amyloidosis space. The analyst expects a "smooth regulatory process" for patisiran and broad label enabling use in the mutant mixed FAC phenotype. Rama raised his price target for Alnylam shares to $162 from $86.
11/08/17
LEHM
11/08/17
NO CHANGE
Target $158
LEHM
Overweight
Alnylam price target raised to $158 from $127 at Barclays
Barclays analyst Gena Wang raised her price target for Alnylam Pharmaceuticals to $158 saying the company highlighted multiple pipeline progresses during the Q3 earnings call. The analyst keeps an Overweight rating on the shares.

TODAY'S FREE FLY STORIES

SYF

Synchrony

$37.30

-0.76 (-2.00%)

08:28
01/19/18
01/19
08:28
01/19/18
08:28
Technical Analysis
Technical Take: Synchrony falls after results »

In the pre-market the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jan

SM

SM Energy

$25.69

-0.93 (-3.49%)

08:28
01/19/18
01/19
08:28
01/19/18
08:28
Conference/Events
SM Energy management to meet with JPMorgan »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

  • 24

    Jan

SBNY

Signature Bank

$153.44

5.39 (3.64%)

08:28
01/19/18
01/19
08:28
01/19/18
08:28
Recommendations
Signature Bank analyst commentary  »

Signature Bank price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SRPT

Sarepta

$61.84

0.67 (1.10%)

08:28
01/19/18
01/19
08:28
01/19/18
08:28
Recommendations
Sarepta analyst commentary  »

Sarepta price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TEAM

Atlassian

$55.60

0.73 (1.33%)

08:27
01/19/18
01/19
08:27
01/19/18
08:27
Recommendations
Atlassian analyst commentary  »

Morgan Stanley says…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

ORMP

Oramed

$8.36

-0.06 (-0.71%)

08:27
01/19/18
01/19
08:27
01/19/18
08:27
Hot Stocks
Oramed CEO: 2018 will be an exciting and event driven year »

In a letter to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ADSK

Autodesk

$112.55

-0.45 (-0.40%)

, CBG

CBRE Group

$45.19

0.2 (0.44%)

08:26
01/19/18
01/19
08:26
01/19/18
08:26
Conference/Events
Bay Area Council Economic Institute to hold a conference »

11th Annual Forecast…

ADSK

Autodesk

$112.55

-0.45 (-0.40%)

CBG

CBRE Group

$45.19

0.2 (0.44%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jan

  • 08

    Feb

08:25
01/19/18
01/19
08:25
01/19/18
08:25
Conference/Events
Federal Reserve Bank of San Francisco President speaks at conference »

Federal Reserve Bank of…

CPLA

Capella Education

$79.80

-0.55 (-0.68%)

, STRA

Strayer

$92.18

-0.64 (-0.69%)

08:25
01/19/18
01/19
08:25
01/19/18
08:25
Conference/Events
Strayer to host special shareholder meeting »

Special shareholder…

CPLA

Capella Education

$79.80

-0.55 (-0.68%)

STRA

Strayer

$92.18

-0.64 (-0.69%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jan

  • 19

    Jan

EXEL

Exelixis

$27.86

0.37 (1.35%)

, IPSEY

Ipsen

$33.90

-0.24 (-0.70%)

08:25
01/19/18
01/19
08:25
01/19/18
08:25
Conference/Events
Exelixis and Ipsen co-host a financial community briefing »

Exelixis and Ipsen…

EXEL

Exelixis

$27.86

0.37 (1.35%)

IPSEY

Ipsen

$33.90

-0.24 (-0.70%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jan

  • 19

    Jan

  • 19

    Jan

  • 25

    Jan

  • 08

    Feb

  • 15

    Feb

OCUL

Ocular Therapeutix

$5.54

-0.02 (-0.36%)

08:24
01/19/18
01/19
08:24
01/19/18
08:24
Upgrade
Ocular Therapeutix rating change  »

Ocular Therapeutix…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

08:24
01/19/18
01/19
08:24
01/19/18
08:24
Conference/Events
Federal Reserve Bank of Atlanta President speaks at breakfast meeting »

Federal Reserve Bank of…

IBM

IBM

$169.12

0.47 (0.28%)

08:23
01/19/18
01/19
08:23
01/19/18
08:23
Recommendations
IBM analyst commentary  »

IBM price target raised…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$DJT

DJ Transportation Average

08:22
01/19/18
01/19
08:22
01/19/18
08:22
Technical Analysis
DJ Transportation Average: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$DJU

DJ Utility Average

08:21
01/19/18
01/19
08:21
01/19/18
08:21
Technical Analysis
DJ Utility Average: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DJX

Dow Jones Industrial Average

08:21
01/19/18
01/19
08:21
01/19/18
08:21
Technical Analysis
Dow Jones Industrial Average: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IYT

iShares Transportation Average

$203.27

0.12 (0.06%)

08:21
01/19/18
01/19
08:21
01/19/18
08:21
Technical Analysis
iShares Transportation Average: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XLK

Technology Select Sector SPDR

$67.67

0.12 (0.18%)

08:20
01/19/18
01/19
08:20
01/19/18
08:20
Technical Analysis
Technology Select Sector SPDR: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XLE

Energy Select Sector SPDR

$76.48

-0.63 (-0.82%)

08:20
01/19/18
01/19
08:20
01/19/18
08:20
Technical Analysis
Energy Select Sector SPDR: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XLY

Consumer Discretionary Sector SPDR

$104.69

-0.09 (-0.09%)

08:20
01/19/18
01/19
08:20
01/19/18
08:20
Technical Analysis
Consumer Discretionary Sector SPDR: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LNC

Lincoln National

$83.06

0.08 (0.10%)

08:19
01/19/18
01/19
08:19
01/19/18
08:19
Conference/Events
Lincoln National to host conference call »

Conference call to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jan

  • 01

    Feb

XLB

S&P Select Materials SPDR

$62.90

-0.04 (-0.06%)

08:19
01/19/18
01/19
08:19
01/19/18
08:19
Technical Analysis
S&P Select Materials SPDR: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XLU

Utilities SPDR

$50.14

-0.32 (-0.63%)

08:19
01/19/18
01/19
08:19
01/19/18
08:19
Technical Analysis
Utilities SPDR: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XLP

Consumer Staples Sector SPDR

$57.39

-0.17 (-0.30%)

08:19
01/19/18
01/19
08:19
01/19/18
08:19
Technical Analysis
Consumer Staples Sector SPDR: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XLV

Health Care Select Sector SPDR

$88.11

0.02 (0.02%)

08:18
01/19/18
01/19
08:18
01/19/18
08:18
Technical Analysis
Health Care Select Sector SPDR: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.